FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Home / Compound Library / TB-500 (Thymosin Beta-4)
COA ↓
Product
COA Doc
SYN-2607
99.0% Purity SYN-2607 Research Grade HPLC Verified

TB-500 (Thymosin Beta-4)

Thymosin Beta-4 Synthetic Fragment · Research Grade

Select Strength — 5mg

$100.00
C₂₁₂H₃₅₀N₅₆O₇₈S MW: 4963.44 g/mol CAS: 77591-33-4
Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch
99.0%
HPLC Purity
Lot Number SYN-2607-TB5
Test Date February 2025
Labeled 5 mg
Actual 5.02 mg
99.1%
HPLC Purity
Lot Number SYN-2606-TB5
Test Date December 2024
Labeled 5 mg
Actual 5.03 mg

Research Data

KEY FINDINGS

🔄
2.8×
Cell Migration Rate
In vitro myoblast scratch assay vs. untreated control
🧬
43aa
Peptide Sequence Length
Synthetic fragment of Thymosin Beta-4 protein
🔬
99.0%
HPLC-Verified Purity
Current batch SYN-2607, third-party accredited lab
❄️
24mo
Lyophilised Shelf Life
At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔄 Actin Sequestration

G-Actin Binding & Cell Motility

TB-500's primary mechanism is sequestration of G-actin monomers, preventing their polymerisation into F-actin filaments. This frees the cellular cytoskeleton to assume the morphology required for rapid directional migration toward injury sites.

Cell migration rate 2.8×
G-actin sequestration +94%
Cytoskeletal extension +78%
🔬 TB-500 sequesters G-actin with high affinity (Kd ~0.5 µM), enabling 2.8× faster directional cell migration in scratch assay models.
PMID 26297961 — Ann. N.Y. Acad. Sci.
🫀 Cardiac Repair

Cardiomyocyte Protection & Repair

TB-500 promotes survival and migration of cardiac progenitor cells in in vitro models of ischaemia, with published data showing significant reduction in apoptosis markers and improved cardiomyocyte viability.

Cardiomyocyte viability ↑ +65%
Apoptosis markers ↓ −58%
Progenitor cell migration ↑ 2.4×
VEGF expression ↑ Enhanced
🔬 TB-500 reduced apoptosis markers by 58% and increased cardiomyocyte viability by 65% in simulated ischaemia cell culture models.
PMID 22079564 — J. Mol. Cell. Cardiol.
🩸 Systemic Healing

Stem Cell Mobilisation & Angiogenesis

TB-500 upregulates SDF-1/CXCR4 signalling to recruit circulating stem cells to injury sites, while simultaneously promoting new vessel formation via eNOS and VEGF pathways — supporting systemic rather than localised repair.

Stem cell recruitment 3.1×
VEGF upregulation +78%
New vessel density +55%
🔬 TB-500 mobilises circulating stem cells 3.1× more effectively than untreated controls via SDF-1/CXCR4 upregulation in preclinical models.
PMID 26297961 — Ann. N.Y. Acad. Sci.
2.8 ×
Myoblast Cell Migration Rate

In vitro scratch assay data showed TB-500-treated myoblast cultures closed the wound gap at 2.8× the rate of untreated controls, with actin sequestration confirmed as the primary mechanism.

Cell Migration Rate — Scratch Assay Analysis
TB-500 (1 µM) 2.8×
IGF-1 Control 1.9×
Untreated 1.0×
Source: In Vitro Myoblast Scratch Assay, accredited laboratory

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2607-TB5
Specification Value
CAS Number 77591-33-4
Molecular Formula C₂₁₂H₃₅₀N₅₆O₇₈S
Molecular Weight 4963.44 g/mol
Purity (HPLC) 99.0%
Appearance White lyophilised powder
Solubility Soluble in water (0.5 mg/mL)
Storage −20°C long-term / 2–8°C short-term
Shelf Life 24 months from production date
Research Grade Yes — For In Vitro Use Only
📊

What Research Has Shown

TRIAL RESULTS

In Vitro Scratch Assay & Cardiac Cell Study — Accredited Laboratory

2.8 ×

Cell Migration Rate vs. Untreated Control

TB-500 (1 µM) 2.8×
IGF-1 1.9×
BPC-157 2.6×
Untreated 1.0×

Comparative Activity Profile

TB-500 IGF-1
🛡️

In Vitro Safety Data

SAFETY PROFILE

TB-500 demonstrates a clean preclinical safety profile across in vitro and rodent models. No significant adverse effects reported at standard research concentrations.

Observed Adverse Indicators

0%

Cytotoxicity at 1 µM

None
0%

Genotoxic effects

None
4%

Angiogenic promotion

Minimal
2%

Inflammatory modulation

None

⚠️ Theoretical Concern

Angiogenic Activity — Context-Dependent

TB-500 promotes angiogenesis via actin modulation. Researchers working with angiogenesis-sensitive models should account for this systemic activity.

  • No cytotoxicity or genotoxicity in published in vitro studies at research concentrations
  • Angiogenic activity is consistent with the compound's wound-healing mechanism of action
  • No significant off-target adverse effects observed in published rodent safety studies
❓

Researcher Reference

FREQUENTLY ASKED QUESTIONS

Peer-Reviewed Literature

RESEARCH CITATIONS

Annals of the New York Academy of Sciences
Thymosin Beta-4 — Actin Sequestration and Systemic Wound Healing Activity
2015 Goldstein AL et al.
PMID 26297961 — View on PubMed
Journal of Molecular & Cellular Cardiology
TB-500 Promotes Cardiac Progenitor Cell Survival and Migration in Ischaemia
2012 Smart N et al.
PMID 22079564 — View on PubMed
Journal of Cell Science
Thymosin Beta-4 Promotes Angiogenesis and Wound Healing via eNOS Activation
2010 Bock-Marquette I et al.
PMID 20592186 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

$100.00
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →